Premium
Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high‐performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study
Author(s) -
Ohtsu Yoshiaki,
Takanuki Fumiyo,
Fukunaga Yasuhisa,
Noguchi Kiyoshi
Publication year - 2015
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.3262
Subject(s) - chemistry , chromatography , high performance liquid chromatography , calibration curve , pharmacokinetics , fluorescence , acetic acid , acetonitrile , fluorescence spectroscopy , extraction (chemistry) , detection limit , pharmacology , biochemistry , medicine , physics , quantum mechanics
The potent phosphodiesterase 4 inhibitor ASP3258 contains a carboxylic acid moiety and a naphthyridine ring and is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease. To support the drug development of ASP3258, we developed and validated a simple method for its determination in rat plasma. Following the addition of the analog AS1406604‐00 as an internal standard, plasma samples were processed using C 18 ‐bonded solid‐phase extraction cartridges under acidic conditions and injected into a high‐performance liquid chromatography system with fluorescence detection. Chromatographic separation was achieved on a Shiseido Capcell Pak C 18 UG120 column (3.0 × 150 mm, 5 µm) with a mobile phase consisting of acetonitrile–0.5% acetic acid (50:50, v/v). HPLC eluent was monitored with a fluorescence detector set at a wavelength of 315 nm for excitation and 365 nm for emission. The calibration curve was linear over a range of 2.5–250 ng/mL. Validation data demonstrated that the method is selective, sensitive and accurate. In addition, the present method was successfully applied to rat plasma samples from a pharmacokinetic study. Copyright © 2014 John Wiley & Sons, Ltd.